US FDA approves durvalumab for unresectable stage III NSCLC

Tthe US Food and Drug Administration (FDA) has approved durvalumab for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2sGvDGo
via IFTTT